Table 2.

Comparison of therapeutic effect and toxicity of dEpoB with different doses, solvents, schedules, and routes of administration in nude mice bearing MX-1 xenografts

Dose, mg/kg	Schedule	Solvent*	Route	Average tumor size (T/C)†	Tumor free mice/total mice	Toxicity death/total mice
15	Q2D  ×  5	DMSO	i.p. injection	0.41	0/5	0/5
20	Q2D  ×  8	DMSO	i.p. injection	0.33‡	0/5	0/5
25	Q2D  ×  5	DMSO	i.p. injection	0.04	0/6	0/6
35	Q2D  ×  5	DMSO	i.p. injection	0.02	3/10 (6, 8, 10)¶	0/10
15	Q2D  ×  5	C/EtOH	i.v. 30-min infusion	ND	ND	4/6 (15, 15, 15, 17)¶
20	Q2D  ×  2	C/EtOH	i.v. 1-min injection	ND	ND	1/1 (4)
20	Q2D  ×  5	C/EtOH	i.v. 30-min infusion	ND	ND	6/6 (10, 10, 11, 11, 11, 11)
20	Q2D  ×  1	C/EtOH	i.p. injection	ND	ND	1/1 (3)
30	Q2D  ×  5	C/EtOH	i.v. 2-hr infusion	ND	ND	2/3 (10, 10)
30	Q2D  ×  6	C/EtOH	i.v. 6-hr infusion	0	5/5 (8, 12, 12, 12, 12)	0/5
30	Q1D  ×  4	C/EtOH	i.v. 6-hr infusion	ND	ND	1/1 (6)
30	Q2D  ×  4	C/EtOH	i.v. 24-hr infusion	0, ND	1/2 (10)	1/2 (12)
60	Q4D  ×  2	C/EtOH	i.v. 24-hr infusion	0, ND	1/2 (12)	1/2 (16)
50	Q2D  ×  5	PEG§	oral	0.68	0/1	0/1

ND, not determined (mice died). MX-1, human mammary carcinoma, 50 mg per mouse implanted s.c. into mice on day 0. Treatments started on day 10. Q2D, every other day. 

^*DMSO: Dimethylsulfoxide 40 μl per mouse; C/EtOH: Cremophor/EtOH (1:1), 100 μl for i.p. injection; 100 μl + saline 0.2 ml for 1-min i.v. or 30-min injection; 100 μl + saline (3–5 ml) for 2–24 hr i.v. infusions. 

^†Average tumor size of treated group/average tumor size of the control group at 2 days after the last dose. 

^‡B-16 melanoma tumor xenograph for this group; all other groups were for MX-1 xenografts. 

^§Polyethylene glycol-400/ethanol (10:1). 

^¶The numbers in parenthesis refer to the number of days that mice, after the beginning of treatment, were tumor-free or the number of days before death due to toxicity after the beginning of treatment.